Avid Bioservices Inc (CDMO)

[jakedogman1]

Here are three summaries of the AACR posters which represents outside party validation of the IP. Other outside party validation includes UTSW and Duke. Next post will highlight the potential of the ps exosome method of detecting ovarian cancer and the current mri methods.

And the IP is valued at zero? The collective market cap of the pdl portion of the five players has got to be over $100 bil and with IP smack dab in the middle of the I-O contest/war, there is zero value for the PPHM IP?

IMO once the clouds go away, the institutions will play. So what are the clouds?

http://peregrineinc.com/images/stories/pdfs/aacr2017kallinteris.pdf

Among patients who received subsequent immunotherapy, a significant improvement in OS was observed for patients in the D+B compared to D+P; HR=0.43, p=0.005. No difference in OS was observed between the two treatment groups for patients who did not receive subsequent immunotherapy. Analysis by both IFN-? and SACT-IO classifications confirmed a statistically significant difference in OS favoring the D+B group among patients with low pretreatment IFN-? who received subsequent IO (HR= 0.24, p<0.001). No OS difference was observed between D+B and D+P for patients with high pretreatment IFN-? regardless of subsequent IO. These data support the mechanistic hypothesis that bavituximab may modulate immune response to enhance the activity of immunotherapy agents. Clinical trials combining bavituximab and immunotherapy agents such as checkpoint inhibitors are planned.

http://peregrineinc.com/images/stories/pdfs/aacr2017hirschhorn.pdf

Anti-OX40 (OX86) activate transferred anti-melanoma CD4+ T cell systemically. The CD4+ T cells migrate to tumor and melanocyte-rich tissues such as ear pinnae. This causes tumor regression but also triggers inflammatory destruction of healthy tissues.
• PS targeting decreases tumor-induced immunosuppression. Transferred antimelanoma CD4+ T cells migrate to tumors and promote tumor regression without offtarget side effects.
• PS targeting is a desirable strategy that can improve the potency of anti-tumor strategies with known clinical off-target effects such as adoptive T cell transfer.
• PS targeting can be combined with CAR T cells to enhance anti-tumor potential.

http://peregrineinc.com/images/stories/pdfs/aacr2017budhu.pdf

• Irradiation of B16 melanoma tumors causes an increase in Phosphatidylserine expression on the surface of both tumor and immune cells.
• mch1N11 in combination with RT or triple combination with mch1N11, RT, and anti-PD-1 led to a significant reduction in tumor burden and greater overall survival benefit.
• Analysis of systemic immune responses in the spleen and draining lymph nodes revealed an increase in CD8 T cell activation, effector cytokine production and differentiation into effector memory cells in the triple combination of RT, mch1N11, and anti-PD-1.
• Analysis of local immune responses in the tumors of treated animals revealed an increase in tumor
associated macrophages and a shift in macrophage polarization towards an M1 pro-inflammatory phenotype after treatment with RT and mch1N11.
• Gene expression analysis of myeloid cells isolated from tumors and draining lymph nodes 2 and 5 days after treatment with RT and mch1N11 show a decrease in expression of anti-inflammatory genes and and increase in expression of pro-inflammatory genes.
• Our data will potentially inform the design of clinical studies combining PS targeting with radiation therapy and/or checkpoint blockade